Investigational zoldonrasib was well tolerated and showed encouraging clinical activity in previously treated KRAS ...
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...
Daraxonrasib, a pancreatic cancer drug from Revolution Medicines, is showing unprecedented success. For patients like Leanna ...
Early results presented at a cancer research conference showed tumor shrinkage and slowed disease progression in patients who ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...
“Setidegrasib is the first drug in this KRAS degrader class targeting KRAS G12D in solid tumors,” lead investigator Wungki ...
You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results